Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders.
BACKGROUND
Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main problem.


OBJECTIVE
Our aim was to evaluate the usefulness of CD45 expression in the immunological classification of BCLPDs.


METHODS
A prospective study was set in a university hospital to investigate the CD45 intensity, particularly in B-CLL.


METHODS
The expression of CD45 in 37 patients with BCLPD including typical B-CLL (Group I), atypical B-CLL and CLL/PLL (II), and hairy cell leukemia (HCL), B-prolymphocytic leukemia (B-PLL), and B-non Hodgkin's lymphoma (B-NHL) as non-CLL BCLPDs (III) and in eight healthy age matched controls (IV) was quantitatively compared by flow cytometric CD45/RALS gating strategy.


METHODS
The mean, median, and peak channel scores of CD45 obtained for the four groups were compared using one-way analysis of variance test. A P value


RESULTS
Lower CD45 density is associated highly with typical CLL and differences between typical CLL and other groups were significant (P< 0.001, 0.001, and 0.001). Non-CLL cases had significantly brighter CD45 expression than atypical CLL (P=0.014). No differences were found between normal lymphocytes and non-CLL BCLPD cases.


CONCLUSIONS
CD45 is a useful marker, to discriminate the typical CLL from the non-CLL BCLPD and from atypical CLL.
Department of Hematology and Oncology, Gazi Tabatabaei Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. shmaljaei@yahoo.com
Seyyed Hadi
SH
Maljaei
Iraj
I
Asvadi-E-Kermani
Jamal
J
Eivazi-E-Ziaei
Alireza
A
Nikanfar
Jalil
J
Vaez
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D003937:Diagnosis, Differential; D005260:Female; D005434:Flow Cytometry; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D015448:Leukemia, B-Cell / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D017493:Leukocyte Common Antigens / Q000097:blood / Q000276:immunology*; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000276:immunology; D008875:Middle Aged; D010750:Phosphoproteins / Q000096:biosynthesis* / Q000276:immunology; D011446:Prospective Studies
D015415:Biomarkers; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; C090519:PTPRCAP protein, human; D010750:Phosphoproteins; D017493:Leukocyte Common Antigens